Sapphiros’ Acquisition Of Biocrucible

Mills & Reeve has acted for the majority shareholders of Biocrucible.

The acquisition by Sapphiros will provide further investment and operational support to accelerate Biocrucible’s platform to market. 

Biocrucible is a leading molecular diagnostics company which applies novel isothermal amplification methods to disposable and point-of-care diagnostic technologies, and seeks to enhance the behaviour and kinetics of engineered biological systems through the use of its Molten Tags™ technology.

The platform is currently being developed for the detection of SARS-CoV-2, although the technology can also be used for the detection of other respiratory and non-respiratory pathogens.

Sapphiros, founded by KKR, a leading global investment firm, and Namal Nawana, the former CEO of both Smith & Nephew and Alere, has been established to invest in growth-stage companies offering sophisticated near-patient diagnostic technologies.

Mills & Reeve acted for the majority shareholders of Biocrucible with principal associate Katharine Robinson (Picture).


Involved fees earner: Katharine Robinson – Mills & Reeve LLP;

Law Firms: Mills & Reeve LLP;

Clients: David Brooks; Helen Kent-Armes; Niall Armes;

Author: Federica Tiefenthaler